T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …

The development of neoplasia involves a complex and continuous interplay between
malignantly transformed cells and the tumour microenvironment (TME). Cancer …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Tissue localization is a critical determinant of T cell immunity. CD8+ T cells are contact-
dependent killers, which requires them to physically be within the tissue of interest to kill …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

CD4+ T cells play key roles in a range of immune responses, either as direct effectors or
through accessory cells, including CD8+ T lymphocytes. In cancer, neoantigen (NeoAg) …

Recent advances in immunotherapy have affirmed the curative potential of T cell-based
approaches for treating relapsed and refractory cancers. However, the therapeutic efficacy is …

The accumulation of acidic metabolic waste products within the tumor microenvironment
inhibits effector functions of tumor-infiltrating lymphocytes (TILs). However, it remains …